Research programme: HIV-RNase H inhibitors - Astex Pharmaceuticals

Drug Profile

Research programme: HIV-RNase H inhibitors - Astex Pharmaceuticals

Latest Information Update: 19 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals
  • Class
  • Mechanism of Action Ribonuclease H inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Mar 2012 Discontinued for HIV infections in United Kingdom (unspecified route)
  • 12 Sep 2011 SuperGen is now called Astex Pharmaceuticals
  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top